Gene transfer to T lymphocytes has historically relied on retro and lentivirus, but recently transposon-based gene transfer is rising as a simpler and straight forward approach to achieve stable transgene expression. Transfer of expression cassettes to T lymphocytes remains challenging, being based mainly on commercial kits. Aims We herein report a convenient and affordable method based on in house made buffers, generic cuvettes and utilization of the widely available Lonza nucleofector II device to promote efficient gene transfer to T lymphocytes. Results This approach renders high transgene expression levels in primary human T lymphocytes (mean 45%, 41–59%), the hard to transfect murine T cells (mean 38%, 36–42% for C57/BL6 strain) and human Jurkat T cell line. Cell viability levels after electroporation allowed further manipulations such as in vitro expansion and Chimeric Antigen Receptor (CAR) mediated gain of function for target cell lysis. Conclusions We describe here an efficient general protocol for electroporation based modification of T lymphocytes. By opening access to this protocol, we expect that efficient gene transfer to T lymphocytes, for transient or stable expression, may be achieved by an increased number of laboratories at lower and affordable costs.
References
[1]
Ebert O, Finke S, Salahi A, Herrmann M, Trojaneck B, et al. (1997) Lymphocyte apoptosis: induction by gene transfer techniques. Gene therapy 4: 296–302.
[2]
Salmon P, Kindler V, Ducrey O, Chapuis B, Zubler RH, et al. (2000) High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96: 3392–3398.
[3]
Serafini M, Bonamino M, Golay J, Introna M (2004) Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis. haematologica 89: 86–95.
[4]
Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, et al. (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nature Biotechnology 24: 687–696 doi:10.1038/nbt1216.
[5]
Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, et al. (2009) Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy. Science 326: 818–823 doi:10.1126/science.1171242.
[6]
Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719–1724.
[7]
Bonamino M, Serafini M, D'Amico G, Gaipa G, Todisco E, et al. (2004) Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors. Gene Therapy 11: 85–93 doi:10.1038/sj.gt.3302141.
[8]
Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, et al. (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. New England Journal of Medicine 365: 1673–1683.
[9]
Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine 14: 1264–1270 doi:10.1038/nm.1882.
[10]
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, et al. (2011) T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Science Translational Medicine 3: 95ra73–95ra73 doi:10.1126/scitranslmed.3002842.
[11]
Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. New England Journal of Medicine 365: 725–733.
[12]
Brenner MK (2012) Will T-cell therapy for cancer ever be a standard of care? Cancer Gene Therapy. Available: http://www.nature.com/doifinder/10.1038/？cgt.2012.74.Accessed 17 October 2012.
[13]
Apollonio F, Liberti M, Marracino P, Mir L (2012) Electroporation mechanism: Review of molecular models based on computer simulation. Antennas and Propagation (EUCAP), 2012 6th European Conference on. pp. 356–358. Available: http://ieeexplore.ieee.org/xpls/abs_all.？jsp?arnumber=6206719. Accessed 26 September 2012.
Murakami T, Sunada Y, others (2011) Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances. Current gene therapy 11. Available: http://ukpmc.ac.uk/abstract/MED/22023474. Accessed 26 September 2012.
[16]
Van Tendeloo VFI, Ponsaerts P, Lardon F, Nijs G, Lenjou M, et al. (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98: 49–56.
[17]
Bell MP, Huntoon CJ, Graham D, McKean DJ (2001) The analysis of costimulatory receptor signaling cascades in normal T lymphocytes using in vitro gene transfer and reporter gene analysis. Nat Med 7: 1155–1158 doi:10.1038/nm1001-1155.
[18]
Zhao Y, Zheng Z, Cohen C, Gattinoni L, Palmer D, et al. (2006) High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation. Molecular Therapy 13: 151–159 doi:10.1016/j.ymthe.2005.07.688.
[19]
Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, et al.. (2013) Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood.Journal of Visualized Experiments. Available: http://www.jove.com/video/50070/clinical？-application-sleeping-beauty-artificial-？antigen-presenting. Accessed 21 February 2013.
[20]
Hackett PB, Largaespada DA, Cooper LJ (2010) A Transposon and Transposase System for Human Application. Molecular Therapy 18: 674–683 doi:10.1038/mt.2010.2.
[21]
Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, et al. (2012) Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies. Human Gene Therapy 23: 444–450 doi:10.1089/hum.2011.167.
[22]
Huang X, Guo H, Tammana S, Jung Y-C, Mellgren E, et al. (2010) Gene Transfer Efficiency and Genome-Wide Integration Profiling of Sleeping Beauty, Tol2, and PiggyBac Transposons in Human Primary T Cells. Molecular Therapy 18: 1803–1813 doi:10.1038/mt.2010.141.
[23]
Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology 12: 269–281 doi:10.1038/nri3191.
[24]
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, et al. (2011) Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research 17: 4550–4557 doi:10.1158/1078-0432.CCR-11-0116.
[25]
Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Current Opinion in Immunology 21: 233–240 doi:10.1016/j.coi.2009.03.002.
[26]
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, et al. (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116: 4099–4102 doi:10.1182/blood-2010-04-281931.
[27]
Chicaybam L, Laino Sodré A, Bonamino M (2011) Chimeric Antigen Receptors in Cancer Immuno-Gene Therapy: Current Status and Future Directions. International Reviews of Immunology 30: 294–311 doi:10.3109/08830185.2011.595855.
[28]
Scholler J, Brady TL, Binder-Scholl G, Hwang W-T, Plesa G, et al. (2012) Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells. Science Translational Medicine 4: 132ra53–132ra53 doi:10.1126/scitranslmed.3003761.
[29]
Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, et al. (2008) Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System. Cancer Res 68: 2961–2971 doi:10.1158/0008-5472.CAN-07-5600.
[30]
Jin Z, Maiti S, Huls H, Singh H, Olivares S, et al. (2011) The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Therapy 18: 849–856 doi:10.1038/gt.2011.40.
[31]
Peng PD, Cohen CJ, Yang S, Hsu C, Jones S, et al. (2009) Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Therapy 16: 1042–1049 doi:10.1038/gt.2009.54.
[32]
D'Amico G, Bonamino M, Dander E, Marin V, Basso G, et al. (2006) T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy. Leukemia 20: 2015–2024.
[33]
Imai C, Mihara K, Andreansky M, Nicholson IC, Pui C-H, et al. (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18: 676–684 doi:10.1038/sj.leu.2403302.
[34]
Flanagan M, Gimble JM, Yu G, Wu X, Xia X, et al. (2011) Competitive electroporation formulation for cell therapy. Cancer gene therapy 18: 579–586.
[35]
Sutlu T, Nystr？m S, Gilljam M, Stellan B, Applequist SE, et al. (2012) Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy. Human Gene Therapy 23: 1090–1100 doi:10.1089/hum.2012.080.
[36]
Grund EM, Muise-Helmericks RC (2005) Cost efficient and effective gene transfer into the human natural killer cell line, NK92. Journal of Immunological Methods 296: 31–36 doi:10.1016/j.jim.2004.10.008.
[37]
Imai C (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106: 376–383 doi:10.1182/blood-2004-12-4797.
[38]
Tran J, Kung SK (2007) Lentiviral Vectors Mediate Stable and Efficient Gene Delivery into Primary Murine Natural Killer Cells. Molecular Therapy 15: 1331–1339 doi:10.1038/sj.mt.6300184.
[39]
Newrzela S, Cornils K, Li Z, Baum C, Brugman MH, et al. (2008) Resistance of mature T cells to oncogene transformation. Blood 112: 2278–2286 doi:10.1182/blood-2007-12-128751.
[40]
Westwood JA, Murray WK, Trivett M, Shin A, Neeson P, et al. (2008) Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Therapy 15: 1056–1066 doi:10.1038/gt.2008.47.
[41]
Geurts A (2003) Gene transfer into genomes of human cells by the sleeping beauty transposon system. Molecular Therapy 8: 108–117 doi:10.1016/S1525-0016(03)00099-6.
[42]
Galla M, Schambach A, Falk CS, Maetzig T, Kuehle J, et al. (2011) Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. Nucleic Acids Research 39: 7147–7160 doi:10.1093/nar/gkr384.
[43]
Lehner M, G？tz G, Proff J, Schaft N, D？rrie J, et al. (2012) Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection. PLoS ONE 7: e31210 doi:10.1371/journal.pone.0031210.
[44]
Mitchell DA, Karikari I, Cui X, Xie W, Schmittling R, et al. (2008) Selective Modification of Antigen-Specific T Cells by RNA Electroporation. Human Gene Therapy 19: 511–521 doi:10.1089/hum.2007.115.
[45]
Rabinovich PM, Komarovskaya ME, Wrzesinski SH, Alderman JL, Budak-Alpdogan T, et al. (2009) Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Human gene therapy 20: 51–61.
[46]
Schaft N, D？rrie J, Müller I, Beck V, Baumann S, et al. (2005) A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunology, Immunotherapy 55: 1132–1141 doi:10.1007/s00262-005-0098-2.
[47]
Van Driessche A, Ponsaerts P, Van Bockstaele DR, Van Tendeloo VFI, Berneman ZN (2005) Messenger RNA electroporation: an efficient tool in immunotherapy and stem cell research. Folia Histochem Cytobiol 43: 213–216.
[48]
Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, et al. (2011) Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies. Cancer Research 71: 3516–3527 doi:10.1158/0008-5472.CAN-10-3843.
